Hyderabad, June 12 -- Bharat Biotech International Limited (BBIL), a global leader in vaccine innovation and manufacturing on Thursday announced that it has partnered with GSK plc (LSE/NYSE: GSK) for the ongoing development and potential use of the Shigella vaccine candidate, altSonflex1-2-3.

As per an official release, the agreement marks a critical step in the advancement of this vaccine, targeting Shigellosis--a severe form of bacterial diarrhoea that disproportionately affects children under five in low and middle-income countries.

The in-licensed candidate, altSonflex1-2-3, has already shown encouraging results in early-stage clinical trials.

A Phase 1 study conducted in Europe demonstrated a favourable safety profile and strong i...